Autoinflammatory disease: New mouse models and therapies - 05/01/20
Doi : 10.1016/j.jaci.2019.10.016
Hal M. Hoffman, MD ⁎ 
Division of Pediatric Allergy, Immunology, and Rheumatology, University of California at San Diego and Rady Children’s Hospital of San Diego, La Jolla, Calif
∗Corresponding author: Hal M. Hoffman, MD, UCSD Mail code 0760, 9500 Gilman Dr, La Jolla, CA 92093.UCSD Mail code 07609500 Gilman DrLa JollaCA92093
Key words : Autoinflammatory, cryopyrin-associated periodic syndrome, NLRP3, amyloidoisis, proton pump inhibitor
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: H. M. Hoffman has received funding from the National Institutes of Health, Excell Research, Jecure Thera, and Bristol Myers Squibb; has provided consulting to Novartis Pharm and Regeneron Pharm; has been a speaker for Novartis Pharm; and has been on the Advisory Board for IFM Thera. |
© 2019
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 145 - N° 1
P. 116-118 - janvier 2020 Retour au numéro
Article précédent
- Anaphylactic or tolerant outcomes with IgE
- Toshiaki Kawakami, Yu Kawakami
- Proximity to major roadways and asthma symptoms in the School Inner-City Asthma Study
- Marissa Hauptman, Jonathan M. Gaffin, Carter R. Petty, William J. Sheehan, Peggy S. Lai, Brent Coull, Diane R. Gold, Wanda Phipatanakul
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?